Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODYSSEY DM-DYSLIPIDEMIA: Alirocumab in T2D with Mixed Dyslipidemia
NCT02642159Phase 4Completed
- Sponsor
- Sanofi
- Start
- Mar 2016
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 4 trial of alirocumab in mixed dyslipidemia, sponsored by Sanofi. Started Mar 2016; status: completed.
02
Drugs
alirocumab
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT02642159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02642159.